How China’s strict Covid policies led to supply chain bottlenecks

How China’s strict Covid policies led to supply chain bottlenecks


At the onset of the Covid-19 pandemic, China’s strict “zero-Covid” policies managed to keep Covid-19 at bay. More than two years later, the country’s ongoing controls are still weighing down its economy and stalling global supply chains.

“Zero-Covid has become one of the select drivers of global recession,” Steve Morrison, senior vice president at the Center for Strategic and International Studies, told CNBC in an interview.

Major trade hubs such as Shanghai and Beijing, after responding to waves of omicron-driven infections, require workers to have negative Covid tests to enter public spaces. The demanding quarantine and testing rules have thwarted truckers on roads as well, driving up the amount of time it takes for goods to get to Chinese ports for export.

When it comes to manufacturing, China has forced some companies to operate within a closed-loop system — similar to the “bubble” strategy — where factory workers live on-site. Companies such as Tesla and iPhone manufacturer Foxconn have had to implement closed-loop systems.

That’s not to mention the poor weather, labor challenges and abnormal demand patterns that have also added to supply chain disruptions.

“What supply chains thrive on is predictability,” said Simon Geale, executive vice president of procurement at Proxima, in an interview with CNBC. “And the only thing we can say about China at the moment is that for many businesses, they’re looking at China as being predictably unpredictable.”

Watch the video above to find out how China’s evolving zero-Covid strategies are slowing down global supply chains and whether there’s any relief in sight.



Source

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More
UnitedHealth Group commits to improvements after independent audit, patient backlash
Health

UnitedHealth Group commits to improvements after independent audit, patient backlash

UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Friday released the first results from a sprawling independent audit of its business practices and committed to a wide range of steps to track and implement improvements in three specific areas. The health-care […]

Read More